Cargando…

Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus

Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuruda, Toshihiro, Kato, Johji, Sumi, Takahiro, Mishima, Kazuya, Masuyama, Hiroyuki, Nakao, Hiroyuki, Imamura, Takuroh, Eto, Tanenao, Kitamura, Kazuo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291340/
https://www.ncbi.nlm.nih.gov/pubmed/17969372
_version_ 1782152449896742912
author Tsuruda, Toshihiro
Kato, Johji
Sumi, Takahiro
Mishima, Kazuya
Masuyama, Hiroyuki
Nakao, Hiroyuki
Imamura, Takuroh
Eto, Tanenao
Kitamura, Kazuo
author_facet Tsuruda, Toshihiro
Kato, Johji
Sumi, Takahiro
Mishima, Kazuya
Masuyama, Hiroyuki
Nakao, Hiroyuki
Imamura, Takuroh
Eto, Tanenao
Kitamura, Kazuo
author_sort Tsuruda, Toshihiro
collection PubMed
description Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patients with type 2 diabetes mellitus. One hundred and nine patients with type 2 diabetes mellitus, aged 52 to 93 years, were examined at outpatient clinics for blood, urinary samples, and echocardiography. They were then followed prospectively. During the average follow-up period of 30 months (range, 3 to 37), 15 patients (14%) had cardiovascular events: This was the first event in 5 patients and a recurrence in 10. Cox regression analysis showed that the past event (hazard ratio [HR] 4.819 [95% confidence interval (CI): 1.299–17.881]; p = 0.019) and plasma BNP level (HR 1.007 [95% CI: 1.002–1.012]; p = 0.010] were independently significant factors for the cardiovascular events during the follow-up period. Patients with plasma BNP ≥53 pg/mL and CRP ≥0.95 mg/dL demonstrated the highest incidence in cardiovascular event, compared to those categorized into either or both low levels of BNP and CRP. This study suggests that combination of plasma BNP and CRP measurement provides the additive prognostic information of cardiovascular events in patients with type 2 diabetes mellitus.
format Text
id pubmed-2291340
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-22913402008-04-22 Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus Tsuruda, Toshihiro Kato, Johji Sumi, Takahiro Mishima, Kazuya Masuyama, Hiroyuki Nakao, Hiroyuki Imamura, Takuroh Eto, Tanenao Kitamura, Kazuo Vasc Health Risk Manag Original Research Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patients with type 2 diabetes mellitus. One hundred and nine patients with type 2 diabetes mellitus, aged 52 to 93 years, were examined at outpatient clinics for blood, urinary samples, and echocardiography. They were then followed prospectively. During the average follow-up period of 30 months (range, 3 to 37), 15 patients (14%) had cardiovascular events: This was the first event in 5 patients and a recurrence in 10. Cox regression analysis showed that the past event (hazard ratio [HR] 4.819 [95% confidence interval (CI): 1.299–17.881]; p = 0.019) and plasma BNP level (HR 1.007 [95% CI: 1.002–1.012]; p = 0.010] were independently significant factors for the cardiovascular events during the follow-up period. Patients with plasma BNP ≥53 pg/mL and CRP ≥0.95 mg/dL demonstrated the highest incidence in cardiovascular event, compared to those categorized into either or both low levels of BNP and CRP. This study suggests that combination of plasma BNP and CRP measurement provides the additive prognostic information of cardiovascular events in patients with type 2 diabetes mellitus. Dove Medical Press 2007-08 /pmc/articles/PMC2291340/ /pubmed/17969372 Text en
spellingShingle Original Research
Tsuruda, Toshihiro
Kato, Johji
Sumi, Takahiro
Mishima, Kazuya
Masuyama, Hiroyuki
Nakao, Hiroyuki
Imamura, Takuroh
Eto, Tanenao
Kitamura, Kazuo
Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
title Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
title_full Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
title_fullStr Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
title_full_unstemmed Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
title_short Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
title_sort combined use of brain natriuretic peptide and c-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291340/
https://www.ncbi.nlm.nih.gov/pubmed/17969372
work_keys_str_mv AT tsurudatoshihiro combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT katojohji combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT sumitakahiro combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT mishimakazuya combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT masuyamahiroyuki combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT nakaohiroyuki combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT imamuratakuroh combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT etotanenao combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus
AT kitamurakazuo combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus